Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,044.90 +26.03 (+2.55%)
Streaming Delayed Price Updated: 3:46 PM EDT, May 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Eli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss ↗
Eli Lilly says retatrutide helped obesity trial participants lose up to 28.3% body weight in the Phase 3 TRIUMPH-1 study. 
Via Benzinga
News headline image
Eli Lilly's Next-Gen Obesity Drug Delivers Eye-Popping Weight Loss ↗
Patients lost up to 85 pounds in a study of Eli Lilly's next-generation weight-loss drug, the company said Thursday. 
Via Investor's Business Daily
News headline image
Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:MMA),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Government
News headline image
Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
Analysts project billions in future market value as biotech innovation and consumer demand continue driving the next wave of health performance products 
From MarketNewsUpdates.com
Via GlobeNewswire
Eli Lilly & Co (NYSE:LLY) Proves a Smart Pick for a Rules-Based Dividend Growth Strategy ↗
Via Chartmill
LLY: Eli Lilly & Co. Passes the Affordable Growth (GARP) Screen with Strong Momentum and Fair Valuation ↗
Via Chartmill
News headline image
Could Viking Therapeutics Be the Next Eli Lilly? ↗
Demand for weight loss drugs may fuel growth for more than one player. 
Via The Motley Fool
News headline image
Medicine's Not Going Anywhere: 3 of the Most Resilient Healthcare ETFs ↗
It's tough to think of an industry with more staying power than healthcare. 
Via The Motley Fool
Topics ETFs Retirement
News headline image
Best Weight Loss Drug Stocks to Buy in 2026 ↗
If you are looking for a GLP-1 investment, you can buy the leader, the underdog, or the upstart. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Q1 Rundown: Elanco (NYSE:ELAN) Vs Other Pharmaceuticals Stocks
Looking back on pharmaceuticals stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Elanco (NYSE:ELAN) and its peers. The pha... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook ↗
Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of demand. 
Via MarketBeat
News headline image
Trump's Stock Picks Perfectly Timed With New Medicare Rules: Report ↗
Donald Trump disclosed up to $680,000 in Eli Lilly stock purchases as Medicare initiatives advanced GLP-1 drug coverage. 
Via Benzinga
Topics Government
News headline image
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party ↗
This dark horse in the weight loss drug race is worth keeping on your watch list. 
Via The Motley Fool
News headline image
Eli Lilly Stock: Next Stop $2,000? ↗
The company is riding an incredible tailwind. 
Via The Motley Fool
News headline image
Supreme Court Rejects Eli Lilly Appeal In Medicaid Fraud Case ↗
Supreme Court lets stand $194 million Medicaid fraud award against Eli Lilly in whistleblower case challenging False Claims Act. 
Via Benzinga
Topics Fraud Whistleblower
News headline image
3 Deeply Undervalued Stocks You Can Buy for Less Than $100 Right Now ↗
These stocks could look like steals in a few years. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Could Eli Lilly's Next Weight Loss Drug Waylay Wegovy -- and Even Zap Zepbound? ↗
Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate. 
Via The Motley Fool
News headline image
Is Kailera Therapeutics a Buy After Its Sizzling IPO? ↗
There's a new challenger to the more established players in the weight-loss drug space. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
If You Invested $1000 In Eli Lilly Stock 20 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Buy, Sell, or Hold Novo Nordisk at $46? ↗
Can Novo Nordisk thrive under intense competitive pressures? 
Via The Motley Fool
News headline image
My Top 3 Healthcare Stocks for May 2026 ↗
Healthcare is booming, and these three companies stand to profit handsomely from growing demand for medications and surgeries. 
Via The Motley Fool
News headline image
This Hot Weight-Loss Drug Stock May Have a Surprise Challenger
The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player closely. 
Via Barchart.com
Topics Earnings Lawsuit
News headline image
Should Eli Lilly Investors Worry About Its Newest Rival -- From Within? ↗
Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market. 
Via The Motley Fool
News headline image
Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook ↗
Amphastar Pharmaceuticals (NASDAQ:AMPH) executives said the company is taking steps to address rebate and discounting pressure on BAQSIMI while maintaining its full-year revenue outlook, according to... 
Via MarketBeat
News headline image
This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst ↗
William Blair gives Kailera Therapeutics ($KLRA) an Outperform rating. Learn why analysts see a competitive edge in their GLP-1 assets. 
Via Benzinga
News headline image
Is Novo Nordisk's Rebound for Real--or Just a Head Fake? ↗
The worst might be in the rearview mirror. 
Via The Motley Fool
News headline image
Eli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss ↗
Eli Lilly data shows patients maintain weight loss with Foundayo or lower-dose Zepbound after switching from injectable therapies. 
Via Benzinga
News headline image
1 of Wall Street’s Favorite Stock to Target This Week and 2 We Avoid
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
Topics Retirement
News headline image
Q1 Earnings Roundup: Amphastar Pharmaceuticals (NASDAQ:AMPH) And The Rest Of The Pharmaceuticals Segment
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Eli Lilly (LLY) Stock Trades Up, Here Is Why
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.4% in the afternoon session after the stock continued to rally as the co... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.